# Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

> **NCT06563245** · PHASE2,PHASE3 · RECRUITING · sponsor: **Children's Cancer Group, China** · enrollment: 96 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma
- Child
- Adolescent
- Young Adult
- Metabolic Response
- Survival
- Treatment
- Brentuximab Vedotin
- PET Scan

## Interventions

- **DRUG:** Brentuximab Vedotin for Injection
- **RADIATION:** response-adapted radiation
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** Dacarbazine
- **DRUG:** Tislelizumab Injection
- **DRUG:** Bedamustine

## Key facts

- **NCT ID:** NCT06563245
- **Lead sponsor:** Children's Cancer Group, China
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2029-11-15
- **Final completion:** 2039-11-15
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563245, "Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06563245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*